A more effective HER2-targeting peptide drug conjugate is needed for breast cancer treatment.

Published Date: 17 May 2023

Target specificity, a broad therapeutic indices, and a prolonged circulation half-life are all benefits of antibody-drug conjugates (ADCs). The large size (?150 kDa), which noticeably slows, is an important drawback of ADCs, though.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Potential targets for treating the most common type of liver cancer in children have been identified by a collaborative study.

2.

Study identifies new approach to protect the brain during radiation therapy

3.

While most cancer screenings won't prolong lives, there are still good reasons to continue screening.

4.

Chemo-Free Quadruplet Shows Promise as DLBCL's First Therapy.

5.

Radiation therapy for patients with breast cancer


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot